Promising Phase 2 Data Show Roxadustat Corrected Anemia in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis

SAN FRANCISCO, April 20, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN ) (“FibroGen”), a research-based biopharmaceutical company, today announced that the Clinical Journal of the American Society of Nephrology has published promising results of a Phase 2 study for roxadustat, an investigational therapy for the treatment of anemia in patients with chronic kidney disease (CKD).

The published results show that roxadustat increased and maintained hemoglobin and decreased hepcidin levels in anemic CKD patients when administered using multiple dosing strategies, continuing to support the hypothesis that roxadustat enables coordinated erythropoiesis. These CKD patients received no previous treatment with erythropoiesis-stimulating agents, were not on dialysis, and were treated with roxadustat regardless of baseline iron repletion status.

Of the 143 patients evaluable for efficacy, 92% achieved a hemoglobin response defined as a hemoglobin increase of > 1.0 g/dl from baseline and hemoglobin of > 11.0 g/dl by the end of treatment (up to 16 weeks of treatment in 47 patients, and up to 24 weeks of treatment in 96 patients).

Generally, patients in all cohorts who received higher starting doses of roxadustat demonstrated earlier achievement of the hemoglobin response. Intravenous iron was not permitted throughout the study period although only 52.4% of study patients were iron-replete at baseline.  As has been shown in previously published results from Phase 2 studies, roxadustat increased hemoglobin independently of the patients’ baseline iron repletion and inflammatory status as measured by baseline C–reactive protein levels.  Also consistent with previously seen results, treatment with roxadustat resulted in decreases in hepcidin and in total cholesterol levels: specifically, a decrease in hepcidin levels of 16.9% (P=0.004) and a decrease in total cholesterol levels by a mean (±SD) of 26 (±30) mg/dl (P<0.001) after 8 weeks of therapy.

“In this study, anemia correction was achieved under a range of treatment options including tiered weight as well as fixed-starting-dose strategies. Correction of anemia and maintenance of hemoglobin response were seen at different dose frequencies (two or three times weekly for achievement of hemoglobin response, one or two or three times weekly for maintenance),” said Robert Provenzano, M.D., lead author and chief of the Division of Nephrology, Hypertension & Transplantation, director of Nephrology Research, and director of Acute Dialysis Services at St. John Hospital and Medical Center in Detroit, Michigan. “Secondary analyses showing decreases in hepcidin and increased iron utilization, as well as reductions in total cholesterol levels, suggest roxadustat consistently affects these parameters.”

“This study shows that roxadustat can successfully correct anemia in chronic kidney disease patients who are not yet receiving dialysis,” said Thomas B. Neff, chief executive officer of FibroGen.  “In exploring different dosing regimens, these results show that roxadustat achieved and maintained hemoglobin response at various dose frequencies, and provide continued evidence of roxadustat’s ability to achieve anemia correction without intravenous iron supplementation.  FibroGen and our partners are encouraged by these results as we continue to advance the roxadustat global Phase 3 program and hope to provide a safer and more accessible option for patients.”

About the Study In this randomized, open-label study, 145 patients with anemia (hemoglobin < 10.5 g/dl at baseline) and non-dialysis CKD were randomized into one of six cohorts of approximately 24 patients, each with varying roxadustat starting doses (tiered weight and fixed amounts) and frequencies (two and three times weekly), followed by hemoglobin maintenance with roxadustat one to three times weekly. Treatment duration was 16 or 24 weeks. Intravenous iron was prohibited. The primary end point was the proportion of patients achieving hemoglobin increase of > 1.0 g/dl from baseline and hemoglobin of > 11.0 g/dl by the end of treatment (up to 16 weeks of treatment in 48 patients, and up to 24 weeks of treatment in 97 patients). Secondary analyses included mean hemoglobin change from baseline, iron utilization, hepcidin and serum lipids. Safety was evaluated by frequency and severity of adverse events.

Roxadustat was well tolerated with no drug-related serious adverse events. Treatment-emergent adverse events were reported in 80 percent of all patients in the safety population. The most common adverse events that occurred in greater than 5 percent of patients on roxadustat were nausea, diarrhea, constipation, vomiting, peripheral edema, urinary tract infection, nasopharyngitis, sinusitis, dizziness, headache, and hypertension. The nature and severity of the adverse events were typical for patients with chronic kidney disease.

About Roxadustat (FG-4592) Roxadustat is currently in Phase 3 development as a potential therapy for anemia associated with chronic kidney disease in both patients on dialysis and not on dialysis. Roxadustat is an orally administered small molecule inhibitor of hypoxia-­inducible factor (HIF) prolyl hydroxylase activity. HIF is a protein transcription factor that induces the natural physiological response to conditions of low oxygen, “turning on” erythropoiesis (the process by which red blood cells are produced) and other protective pathways.

AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat (FG-4592) for the treatment of anemia in patients with CKD in the U.S., China, and other markets. Astellas and FibroGen are collaborating on the development and commercialization of roxadustat in Europe, Japan, the Commonwealth of Independent States, the Middle East, and Africa. 

For information about roxadustat studies that are currently recruiting patients, please visit clinicaltrials.gov at this link: https://clinicaltrials.gov/ct2/results?term=r...rch=Search

About Chronic Kidney Disease Chronic kidney disease (CKD) affects more than 200 million people worldwide and more than 30 million adults in the U.S. Although the disease can occur at any age, it becomes more common in aging populations and its prevalence is increasing. Anemia is a common complication of CKD and is associated with significant morbidity and mortality in both the dialysis and non-dialysis populations. In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare issue that represents a large and growing unmet medical need.  Currently, no curative treatment or ability to stop kidney deterioration in patients with CKD exists, with the exception of kidney transplantation.

About FibroGen FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. The company utilizes its extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate development programs in multiple therapeutic areas. Its most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs) in Phase 3 clinical development for the treatment of anemia in CKD.  A second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD).  For more information please visit: www.fibrogen.com .

Forward-Looking Statements This release contains forward-looking statements, including statements regarding the tolerability of roxadustat, the potential ability of roxadustat to maintain anemia correction without ongoing intravenous iron repletion, the potential ability of roxadustat to maintain hemoglobin levels in multiple types of CKD patients being treated for anemia using multiple dosing strategies, and the potential for continued safety or efficacy in roxadustat Phase 3 studies.

Our actual results may differ materially from these early data and any forward-looking statements due to risks and uncertainties that are described in our Annual Report on Form 10-K and our quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contact: Leanne Price 415.978.1200 lprice@fibrogen.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 128

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 154

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 68

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 65

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 63

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading

Top 5 Most Recently Viewed Articles

Smart Mattress Market Expected to Reach USD 2.3 Billion Soon

Updated Category News Views 231

Overview of the Smart Mattress Market Growth Smart mattresses have emerged as key players in the bedding industry, shaped by the rising awareness of sleep's importance to overall health. With a current valuation of approximately USD 1.6 billion in 2023, the market is projected to reach USD 2.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.7% in the...

Continue Reading
VyStar Foundation Celebrates Investment in Kennesaw State Education

Updated Category News Views 178

VyStar Credit Union and Kennesaw State Unveil VyStar Arena The anticipation surrounding the recent unveiling of VyStar Arena at Kennesaw State University is palpable, marking a significant achievement for both the university and VyStar Credit Union. This newly renovated arena will serve as the heart of athletic activities, hosting women's volleyball and men's basketball...

Continue Reading
Google Cloud and Verizon Transform Customer Engagement with AI

Updated Category News Views 599

Google Cloud and Verizon: Pioneering Customer Experience Innovations In a groundbreaking collaboration, Google Cloud has joined forces with Verizon to revolutionize customer service through innovative technology. This partnership leverages Google Cloud's generative AI to enhance the way Verizon serves its customers, resulting in significant improvements in customer...

Continue Reading
Celebrating the Holidays: Joyful Activities for Seniors

Updated Category News Views 161

Bringing Festive Cheer to Seniors This Holiday Season The holiday season is a special time for celebration, togetherness, and creating lasting memories, particularly for our seniors. Executive Home Care is dedicated to enhancing the holiday spirit for seniors by encouraging families and caregivers to engage in joyful activities that uplift and connect the loved ones in...

Continue Reading
Paragon Sports Revolution: NYC Store's Bold Overhaul

Updated Category News Views 32

Paragon Sports Redefines NYC's Retail Scene If you're thinking classic old guard can't innovate, take a gander at Paragon Sports. This 118-year-old New York cornerstone isn't just resting on its laurels as some ancient relic; they're breaking out the playbook for a fresh start in the Big Apple. In a bold move, they’ve decided to not only enhance their in-store...

Continue Reading